GlassScriptPhysician profile
Diana Vucurevich
NPI 1285758540
$1,645.50
in general payments reported to CMS, 2019-2025
23 companies · $599 in 2025
The $599 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.57 · 2022: $125 · 2023: $852 · 2024: $51.10 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $202.54 | 2023-2025 | Breyanzi, Opdivo, Opdualag |
| Pfizer INC. | $179.41 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $171.94 | 2022-2023 | |
| Janssen Biotech, INC. | $168.57 | 2021-2025 | Carvykti, Rybrevant |
| Pharmaessentia USA Corporation | $150.54 | 2023-2025 | Besremi |
| Nevro Corp. | $133.76 | 2023 | Senza |
| Abbvie INC. | $76.82 | 2023-2025 | |
| Puma Biotechnology, INC. | $65.94 | 2023-2025 | |
| Astellas Pharma US INC | $62.92 | 2023 | Xtandi, Xospata |
| Taiho Oncology, INC. | $59.25 | 2022-2023 | |
| Incyte Corporation | $47.36 | 2022 | |
| Genentech USA, INC. | $42.43 | 2023 | Rozlytrek, Alecensa, Gavreto |
| Merck Sharp & Dohme LLC | $35.88 | 2023 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $34.70 | 2023-2025 | Dupixent, Libtayo |
| Acrotech Biopharma INC. | $30.15 | 2023 | Beleodaq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $27.91 | 2023 | |
| Karyopharm Therapeutics INC. | $26.83 | 2023 | Xpovio |
| Sobi, INC | $26.68 | 2023 | |
| Recordati_rare_diseases_inc. | $24.65 | 2023 | Sylvant |
| Astrazeneca Pharmaceuticals LP | $23.49 | 2023 | Imfinzi |
| Horizon Therapeutics Plc | $22.95 | 2023 | Krystexxa |
| Amgen INC. | $16.96 | 2023 | Nplate, Vectibix, Lumakras |
| Daiichi Sankyo INC. | $13.82 | 2023 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Vucurevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.